Invivo T cell costimulation blockade with abatacept foracute graft-versus-host disease prevention: A first-in-disease trial

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 11, 2013, Pages 1638-1649

  Koura, Divya T ^a   Horan, John T ^b   Langston, Amelia A ^a   Qayed, Muna ^b   Mehta, Aneesh ^c   Khoury, Hanna J ^a   Harvey, R Donald ^a   Suessmuth, Yvonne ^c   Couture, Cynthia ^b   Carr, Jennifer ^b   Grizzle, Audrey ^b   Johnson, Heather R ^a   Cheeseman, Jennifer A ^c   Conger, Jason A ^c   Robertson, Jennifer ^c   Stempora, Linda ^c   Johnson, Brandi E ^c   Garrett, Aneesah ^b   Kirk, Allan D ^c   Larsen, Christian P ^c   Waller, Edmund K ^a   Kean, Leslie S ^b,d   more..

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Allogeneic transplantation; Costimulation blockade; Graft versus host disease prophylaxis

Indexed keywords

ABATACEPT; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BACTEREMIA; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CELL STIMULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERSENSITIVITY; IN VIVO STUDY; MALE; MEMORY T LYMPHOCYTE; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RELAPSE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; UNRELATED DONORS; ACUTE DISEASE; ALLOTRANSPLANTATION; COSTIMULATION BLOCKADE; FEASIBILITY STUDY; GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; YOUNG ADULT;

ALLOGENEIC TRANSPLANTATION; COSTIMULATION BLOCKADE; GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84885796022     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.09.003     Document Type: Article

References (44)

1. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
2. Weisdorf D.J., Hurd D., Carter S., et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003, 9:512-518.
3. Lee S.J., Kim H.T., Ho V.T., et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006, 38:305-310.
4. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
5. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
6. Woolfrey A., Klein J.P., Haagenson M., et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:885-892.
7. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
8. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000, 95:3996-4003.
9. Vincenti F. Costimulation blockade in autoimmunity and transplantation. JAllergy Clin Immunol 2008, 121:299-306.
10. Pree I., Wekerle T. Inducing mixed chimerism and transplantation tolerance through allogeneic bone marrow transplantation with costimulation blockade. Methods Mol Biol 2007, 380:391-403.
11. Larsen C.P., Knechtle S.J., Adams A., et al. Anew look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006, 6:876-883.
12. Bour-Jordan H., Esensten J.H., Martinez-Llordella M., et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 2011, 241:180-205.
13. Linsley P.S., Nadler S.G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009, 229:307-321.
14. Chitale S., Moots R. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2008, 8:115-122.
15. Reynolds J., Shojania K., Marra C.A. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. Pharmacotherapy 2007, 27:1693-1701.
16. Linsley P.S., Greene J.L., Brady W., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1:793-801.
17. van der Merwe P.A., Bodian D.L., Daenke S., et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. JExp Med 1997, 185:393-403.
18. Blazar B.R., Taylor P.A., Linsley P.S., et al. Invivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994, 83:3815-3825.
19. Ohata J., Sakurai J., Saito K., et al. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis. Clin Exp Immunol 2002, 129:61-68.
20. Via C.S., Rus V., Nguyen P., et al. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. JImmunol 1996, 157:4258-4267.
21. + T cells as a reservoir of breakthrough T cell proliferation during costimulation blockade and sirolimus-based immunosuppression. Blood 2010, 116:5403-5418.
22. Bristol-Myers Squibb. Orencia package insert. Available from:. Accessed January 2013. http://packageinserts.bms.com/pi/pi_orencia.pdf.
23. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. JClin Oncol 1988, 6:1562-1568.
24. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
25. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
26. Vincenti F., Larsen C.P., Alberu J., et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012, 12:210-217.
27. Hamby K., Trexler A., Pearson T.C., et al. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism. Am J Transplant 2007, 7:1884-1896.
28. Vincenti F., Charpentier B., Vanrenterghem Y., et al. Aphase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
29. Larsen C.P., Pearson T.C., Adams A.B., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5:443-453.
30. Kalwak K., Moson I., Cwian J., et al. Aprospective analysis of immune recovery in children following allogeneic transplantation of T-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors. Transplant Proc 2003, 35:1551-1555.
31. Niederwieser D., Gastl G., Rumpold H., et al. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). BrJ Haematol 1987, 65:301-305.
32. Elmaagacli A.H., Basoglu S., Peceny R., et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic-phase chronic myeloid leukemia. Blood 2002, 99:1130-1135.
33. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003, 101:4260-4266.
34. Wherry E.J., Teichgraber V., Becker T.C., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4:225-234.
35. Kmieciak M., Gowda M., Graham L., et al. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. JTransl Med 2009, 7:89.
36. Furst D.E., Keystone E.C., Braun J., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012, 71(Suppl 2):2-45.
37. Miller A.V., Ranatunga S.K. Immunotherapies in rheumatologic disorders. Med Clin North Am 2012, 96:475-496.
38. Bluestone J.A., St Clair E.W., Turka L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006, 24:233-238.
39. Bruce S.P., Boyce E.G. Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. Ann Pharmacother 2007, 41:1153-1162.
40. Kean L.S., Adams A.B., Strobert E., et al. Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant 2007, 7:320-335.
41. Larsen C.P., Page A., Linzie K.H., et al. An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant 2010, 10:2396-2409.
42. Ramakrishnan S.K., Page A., Farris A.B., et al. Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am JTransplant 2012, 12:1755-1764.
43. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
44. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.